Update on two new projects

Keyword:
Publish time: 25th December, 2023      Source: CCM
Information collection and data processing:  CCM     For more information, please contact us
  

    Summary: Chongqing Abiochem intends to build 2nd phase of its Bio-Industrialisation Site project to produce Reb M and 2′-FL; Huakang Pharma plans to produce polydextrose.   

  

    Abiochem Biotechnology (Chongqing) Co., Ltd. (Chongqing Abiochem) completed the construction and equipment installation of its Bio-Industrialisation Site project with an output of 3,000 t/a of D-ethyl ester, 8,000 t/a of enzyme preparations and 1,470 t/a of by-product ammonium sulphate, and this project is in the process of equipment commissioning. In order to meet the market demand, the company plans to build phase 2 of the Bio-Industrialisation Site project. The local authority accepted and publicised the environmental impact (EI) report of the 2nd phase on 22 Nov. and made it open to the public again on 7 Dec. before granting approval.   

  

        

  

    Overview of Chongqing Abiochem's project (Phase 2):   

  
  •     Construction nature: Expansion   
  •   
  •     Location: Changshou Economic and Technological Development Zone, Chongqing Municipality   
  •   
  •     Total investment: USD16.88 million (RMB120 million), including environmental investment of USD421,917 (RMB3 million)   
  •   
  •     Product scheme:   
  •   
  •     300 t/a of rebaudioside M (Reb M), meeting the National Food Safety Standard–Food Additive: Stevioside (standard ID: GB1886.335–2022)   
  •   
  •     300 t/a of 2′-fucosyllactose (2′-FL), meeting the National Food Safety Standard–Food Additive: Enzyme Preparations for Food Industry (standard ID: GB1886.174–2016)   
  •   
  •     Labour quota: 44 additional employees   
  •   
  •     Working system: Three 8hr shifts per workday, totalling 333 production days a year   
  •   
  •     Construction period: 16 months   
  •   

        Zhejiang Huakang Pharmaceutical Co., Ltd. (Huakang Pharma)'s 10,000 t/a polydextrose technology upgrading project is moving forward—the EI report was accepted by the local authority on 5 Dec.   

      

            

      

        Overview of Huakang Pharma's project:   

      
  •     Construction nature: Expansion   
  •   
  •     Location: Kaihua County, Quzhou City, Zhejiang Province   
  •   
  •     Total investment: USD2.37 million (RMB16.88 million), of which USD35,160 (RMB250,000) for environmental protection, accounting for 1.48%   
  •   
  •     Construction content: Purchase a series of production equipment to build a polydextrose production line in the existing erythritol workshop   
  •   
  •     Product scheme:   
  •   
  •     5,000 t/a of food-grade flavoured polydextrose   
  •   
  •     5,000 t/a of food-grade polydextrose   
  •   
  •     Production process: Polydextrose is produced from glucose, sorbitol and citric acid by mixing and polymerisation at high temperatures, which is then put through the dissolution, refining, concentration, drying and packaging processes to obtain the food-grade polydextrose.   
  •   
  •     Labour quota: No additional labour employed   
  •   
  •     Working system: Three 8hr shifts per workday, totalling 300 working days a year   
  •   
  •     Progress: Construction is scheduled to begin in Dec. 2023 and be completed within 8 months.   
  •   Source:CCM

      

      

      More information can be found at CCM Sweeteners China Monthly Report.

      

    About CCM:

    CCM is the leading market intelligence provider for China's agriculture, chemicals, food & feed and life science markets. Founded in 2001, CCM offers a range of content solutions, from price and trade analysis to industry newsletters and customized market research reports. CCM is a brand of Kcomber Inc.


     
    For more information about CCM, please visit www.cnchemicals.com or get in touch with us directly by emailing econtact@cnchemicals.com or calling +86-20-37616606.